Delivery Order SPE2DB25D3201-SPE2DB26FNNXA
Award Date 11/6/25
Potential Completion Date 12/1/25
Potential Value $24K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $136,567.97 delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials on April 24, 2025, with completion expected by May 15, 2025. This firm fixed-price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency awarded a $63,767.62 delivery order to AmerisourceBergen Drug Corp for Ocrevus 300 mg/10 ml vials on September 8, 2025, with completion targeted for September 29, 2025. This is a firm fixed-price delivery order issued under a non-competitive set-aside arrangement. Ocrevus is a monoclonal antibody used primarily for treating multiple sclerosis, reflecting the pharmaceutical distributor's role in supplying specialized medications to support military and veteran...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of OCREVUS 300 mg/10 mL vials valued at $36,057.84 under a Firm Fixed Price contract type. This delivery order, which is not set-aside and was competitively awarded, is scheduled for completion by September 11, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract represents a child order under...
- The Defense Logistics Agency awarded a $48,077.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Ocrevus 300 mg/10 ml vials on September 26, 2025, with an ultimate completion date of October 20, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ocrevus is a disease-modifying therapy used to treat multiple sclerosis, reflecting the...
- The Defense Logistics Agency awarded a $53,535.55 delivery order to AmerisourceBergen Drug Corp for 4,569,471,727 units of Ocrevus 300 mg/10 mL vials on September 16, 2025, with an ultimate completion date of October 7, 2025. This competitively awarded, firm fixed price contract carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. Ocrevus is a monoclonal antibody treatment used primarily for multiple sclerosis, reflecting the...
- The Defense Logistics Agency awarded a $96,154.24 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials. This delivery order, issued on September 17, 2025, with an ultimate completion date of October 8, 2025, represents a non-set-aside competitive award to support federal medical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this...
- The Defense Logistics Agency (DLA) awarded a $48,077.16 delivery order to AmerisourceBergen Drug Corp for 4,569,852,928 units of Ocrevus 300 mg/10 ml vials. This is a firm fixed price, competitively awarded contract with no set-aside designation, scheduled for completion by November 19, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Ocrevus (ocrelizumab) is a monoclonal antibody therapeutic used to treat multiple...
- The Defense Logistics Agency awarded a delivery order valued at $24,038.58 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on August 18, 2025. The contract is firm fixed price with no set-aside designation and is scheduled for completion by September 9, 2025. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $48,077.16. The contract is firm fixed price with no set-aside designation, indicating competitive award, and is scheduled for completion by August 28, 2025. AmerisourceBergen will perform the work from its corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Ocrevus 300 mg/10 mL vials valued at $32,694.46 under a firm fixed-price contract. The delivery order is non-set-aside and competitively awarded, with a completion date of June 24, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare...